Our business is influenced by the growth in demand for biologic drugs, particularly the global market for monoclonal antibodies (mAbs). Demand for our products is associated with the overall volume of mAbs manufactured; there is little connection to final drug pricing or the clinical or commercial success or failure of an individual biologic drug.
As the number of biologic drugs on the market and in development continues to increase, and as worldwide access to biologics expands with the emergence of biosimilar and bio-better versions of original drugs, biopharmaceutical manufacturers are tasked with reducing the time and cost associated with production while improving yield and retaining the highest levels of product quality.
These market dynamics are driving process intensification and adoption of disposable technologies and other products that offer convenience, flexibility and the ability to improve capacity utilization in the most modern continuous processing facilities as well as in standard batch processing facilities. The bioprocessing products manufactured by Repligen are designed to address these important needs of biopharmaceutical manufacturers in an increasingly competitive environment.